Loading...
Protalix Q1 2025 Earnings Report
Protalix BioTherapeutics reported its first quarter 2025 financial and business results, showing increased revenues and progress in clinical trials.
Key Takeaways
Protalix BioTherapeutics reported a solid first quarter in 2025 with a significant increase in revenues from selling goods. The company is focused on advancing its gout candidate, PRX-115, into a phase II clinical trial later this year, following promising phase I results.
Total revenue for Q1 2025 was $10.113 million, an increase from $3.748 million in Q1 2024.
Net loss for Q1 2025 was $3.619 million, or $0.05 per share, an improvement from a net loss of $4.595 million, or $0.06 per share, in Q1 2024.
The company successfully completed the First-in-Human (FIH) phase I clinical trial of PRX-115, its gout candidate, in 2024.
Protalix plans to initiate a phase II clinical trial for PRX-115 in patients with gout during the second half of 2025.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Protalix BioTherapeutics is focused on advancing its lead gout candidate, PRX-115, into a Phase II clinical trial in the second half of 2025, building on promising Phase I results. The company also continues to evaluate other pipeline candidates for future development.
Positive Outlook
- Successful completion of the First-in-Human (FIH) phase I clinical trial of PRX-115.
- Preliminary results of PRX-115 FIH study demonstrate potential for effective uric acid-lowering treatment with wide dosing interval.
- Plans to initiate a phase II clinical trial for PRX-115 in patients with gout during the second half of 2025.
- Continued evaluation of additional pipeline candidates, including PRX-119 and early-stage clinical assets.
- PRX-115 results were presented at the American College of Rheumatology (ACR) Convergence 2024, indicating positive scientific recognition.
Challenges Ahead
- Further studies are needed to confirm the long-term safety and efficacy of PRX-115.
- Expectation of minimal revenues from license and R&D services other than potential regulatory milestone payments.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...